文献速递临床免疫质量管理与危急值

糖尿病相关自身抗体的血清标本方法学比较

Method comparison of diabetes mellitus associated autoantibodies in serum specimens.
PubMed 文献 · Clin Chem Lab Med · 2025-08-25

该研究比较了三种商用平台检测GADA、IA-2A和ZnT8A的方法学性能。与实验室常规使用的ELISA相比,两种化学发光平台结果一致性不一,GADA和IA-2A检测存在显著差异,部分ELISA阳性患者在其他平台呈阴性或临界值。这些偏差无法通过标准校准和内部质控发现。

要点

  • CLIA与ELISA检测GADA和IA-2A结果差异显著且不可预测。
  • 高达65%的ELISA阳性患者至少一种CLIA平台结果阴性或临界。
  • 方法学偏差无法通过常规校准和内控程序识别。

核心结论

  • CLIA设备与常规ELISA方法检测GADA和IA-2A存在显著且具临床相关性的差异。

研究设计与样本

  • 方法验证研究,比较三种商用平台(EUROLabWorkstation酶联免疫吸附试验、iFlash 1800化学发光免疫分析、Maglumi 800化学发光免疫分析)检测GADA、IA-2A和ZnT8A。

主要发现

  • 与EUROLabWorkstation相比,Maglumi对GADA和IA-2A显示可接受的符合度和偏差(GADA 75.4-35.8%,IA-2A 71.7-50.3%)。
  • iFlash对GADA和IA-2A的符合度和偏差较差(GADA 51.5-108.8%,IA-2A 68-32.5%)。
  • iFlash对ZnT8A显示极好符合度,而Maglumi在200 U/mL阈值下几乎全为阴性,导致严重低估。
  • 三种CLIA设备在所有三项参数上未观察到一致的一致性。
  • ELISA阳性患者中高达65%在至少一种CLIA设备上呈阴性或临界结果。

临床怎么用

  • 检验科医生应意识到不同CLIA平台与ELISA检测糖尿病自身抗体结果存在不可预测的差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Autoantibodies against structure elements of the pancreas are an essential part of laboratory diagnosis of diabetes mellitus. The heterogeneity of current methods and difficult inter-assay comparability of results poses challenges to both clinical interpretation as well as research integrity. METHODS: We conducted a method validation study comparing the measurement of autoantibodies against glutamic acid decarboxylase (GADA), islet antigen 2 (IA-2A), and zinc transporter 8 (ZnT8A) on three commercially available platforms (EUROLabWorkstation analyzer, enzyme-linked immunosorbent assay (ELISA); iFlash 1800 (chemiluminescence immunoassay (CLIA); Maglumi 800 (CLIA)). RESULTS: Compared to the results from EUROLabWorkstation analyzer that was routinely used in our laboratory, the Maglumi demonstrated an acceptable agreement and deviation for GADA (75.4-35.8 %) and IA-2A (71.7-50.3 %). The iFlash displayed less favorable results with agreement and deviation for GADA (51.5-108.8 %) and IA-2A (68-32.5 %). While the iFlash showed excellent agreement for ZnT8A, the Maglumi produced almost exclusively negative results below a 200 U/mL threshold which results in severe underestimation of results on the Maglumi. Overall, no consistent agreement was observed across all three parameters among the CLIA devices tested. CONCLUSIONS: Our study reveals significant and clinically relevant discrepancies in the detection of GADA and IA-2A when comparing CLIA devices to the ELISA method routinely used in our laboratory. For individual antibodies up to 65 % of patients who tested positive using ELISA showed negative or borderline results on at least one CLIA device. These deviations are unpredictable and cannot be detected through standard calibration and internal control procedures.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Lenard A, Rapp A, Busch S, et al. Method comparison of diabetes mellitus associated autoantibodies in serum specimens. Clin Chem Lab Med. 2025. PMID: 40842189. doi:10.1515/cclm-2025-0137

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。